Author(s)

Paul Turner^1,2

¹Koena Pharmaceuticals, Melbourne, Australia.
²Department of Otolaryngology, Faculty of Medicine, Dentistry and Health Sciences, University of Melbourne, Melbourne, Australia.

Inflammatory skin diseases are characterized by the activation of the innate and adaptive immune system via the production of pro-inflammatory cytokines. The main proinflammatory cytokines responsible for this development include TNF-alpha, Interleukin 1, 6 and 17, also the transcription factor NF-kappa B. Small molecule anti-inflammatory compounds such as those detailed in the paper, show much promise in dealing with these skin disorders. Four nutraceutical molecules that are well characterized by their capacity to interact with many of the pro-inflammatory cytokines, importantly IL-17, are found in an Australian product, Koena. Koena has been shown to not only decrease these cytokines but also help increase the production of Interleukin 10 and important anti-inflammatory cytokines. This paper reports clinical benefits of Koena in a variety of circumstances; eczema and psoriasis; insect bites and sting; solar damaged skin and keratosis. An analysis of patient/purchaser reviews via the website Koena.com.au to ascertain what condition they purchased the product for, if any, and the satisfaction rating after use. More than 35% of reviewers reported purchasing Koena to help with inflamed skin. Those reporting being satisfied with the result was 95% for this use. This paper reports on the benefit of small molecule anti-inflammatories in modulating and not blocking an immune response. It also illustrates the benefits of multitherapy when dealing with complex inflammatory responses as opposed to monotherapy.

Cytokines, Inflammatory Skin Disorders, Transcription Factors, Koena

Turner, P. (2023) Koena, a Novel Compound That Dampens Inflammation in the Skin. Journal of Cosmetics, Dermatological Sciences and Applications, 13, 45-52. doi: 10.4236/jcdsa.2023.131005.